← brief for 2026-09-16 · Slowing decline

SGLT2 Inhibitors in Cardiovascular-Kidney-Metabolic Syndrome: Drugs Unifying Heart, Kidney, and Metabolism Pharmacotherapy.

Article No results yet Peer reviewed

Key takeaways

This article reviews what earlier research says about SGLT2 inhibitors. These pills were first made for diabetes and are now used to protect the heart and kidneys. The review covers people who have heart disease, kidney disease and metabolic problems like diabetes all at once. It adds no new data of its own. It only sums up and explains earlier randomized trials for doctors.

Who did this work

Okhovat V · Lybeshari K · Cubeddu LX · Hale G

Source

Article · PubMed, the drug frontier · 2026 Sep 15
https://pubmed.ncbi.nlm.nih.gov/42744984/